帕博利珠单抗获FDA优先审评资格】2025年2月26日,美国FDA已接受该公司为重磅免疫疗法Keytruda(帕博利珠单抗)递交的补充生物制品许可申请(sBLA),寻求批准Keytruda作为手术前的新辅助疗法,用于治疗可切除局部晚期头颈部鳞状细胞癌(LA-HNSCC)患者,随后联合标准放疗(有或无顺铂)作为辅助治疗,然后再作为单药进行辅助治疗。FDA...
头颈部鳞癌(HNSCC)是全球第七大常见癌症,也是我国常见的癌症之一,2015年我国新发病例7.7万,死亡病例3.8万,超过60%的HNSCC患者初诊时为局晚期,且呈逐年上升趋势。局部晚期头颈部鳞状细胞癌(LA SCCHN)患者的预后较差,约50%会出现复发且...
[8] Lin Gui, et al.2023 ASCO. Abstract 6087P.1. [9] 2023 SITC. Abstract # 678.Updated safety and efficacy of toripalimab combined with cetuximab in platinum-refractory recurrent or metastatic head and neck squamo...
美国时间2024年7月12日,作为LAG-3(淋巴细胞激活基因-3)治疗领域的先锋,Immutep公司自主研发的抗LAG3单抗eftilagimod alfa(efti)联合帕博利珠单抗一线治疗PD-L1表达阴性的头颈鳞状细胞癌(HNSCC)患者取得突破性进展: 在TACTI-003(KEYNOTE-PNC-34)IIb期临床试验的Cohort B中,eftilagimod alfa联合帕博利珠单抗,在31名...
Conclusions: IMRT with Hypofractionated concomitant simultaneous integrated boost (SIB) was better than standard IMRT with SIB in LAHNSCC, with respect to radiological response, however, at the cost of higher toxicity.Thimmaiah NaveenK. Sruthi
e23275#Background:Multimodal therapy, including definitive radiotherapy (RT) with or without systemic therapy (ST) or surgery followed by adjuvant RT ± ST is typically recommended for patients (pts) with LA HNSCC treated with curative intent. Assessing real-world use of various treatment modalities...
Comparison of carboplatin with 5-fluorouracil (carbo-5FU) versus cisplatin as concomitant chemoradiotherapy (CRT) for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)' 来自 Semantic Scholar 喜欢 0 阅读量: 28 作者: SH Hanemaaijer,IC Kok,RSN Fehrmann,BVD Vegt,JA Gietema,BEC ...
tend to upregulate both glycolysis and mitochondrial OXPHOS.57,58Furthermore, OXPHOS showed a significant correlation with glycolysis in melanoma and head and neck squamous cell carcinoma (HNSCC) as well as with the response to hypoxia.58,59This suggests that the traditional view of tumor cell meta...
Associations between OS and EFS were strong (R=0.79-0.88), suggesting EFS is a valid surrogate for OS in surgery ineligible LA HNSCC pts receiving CRT. Legal entity responsible for the study Merck & Co., Inc. Funding Merck & Co., Inc. Disclosure C.M. Black: Financial Interests, Personal...
tend to upregulate both glycolysis and mitochondrial OXPHOS.57,58Furthermore, OXPHOS showed a significant correlation with glycolysis in melanoma and head and neck squamous cell carcinoma (HNSCC) as well as with the response to hypoxia.58,59This suggests that the traditional view of tumor cell meta...